Surrozen Inks Strategic Partnership With Boehringer Ingelheim For Retinal Disease Candidate

  • Surrozen Inc SRZN entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for retinal diseases.
  • SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen's SWAP technology. 
  • It is currently being developed for the treatment of retinal vascular-associated diseases. 
  • In preclinical models of retinopathy, SZN-413 could potently stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage.
  • Also See: Surrozen's Q2 Earnings
  • Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop SZN-413 and other Fzd4-specific Wnt-modulating molecules for all purposes, including as a treatment for retinal diseases, for an upfront of $12.5 million. 
  • Surrozen will also be eligible to receive up to $586.5 million in milestone payments.
  • After an initial joint research period, Boehringer Ingelheim will assume all development and commercial responsibilities.
  • Price Action: SRZN shares are up 9.40% at $2.36 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!